Targovax Company Profile

08:53 EDT 17th March 2018 | BioPortfolio

Targovax was started in October 2010 to develop TG01, a vaccine targeting pancreatic cancer. TG01 is based on research from The Radium Hospital and Norsk Hydro in the end of the 90’s. The drug has already been tested in patients, and the company is building on these results. The company is based in Lysaker close to Oslo, Norway, and co-located with Oslo Cancer Cluster.

News Articles [32 Associated News Articles listed on BioPortfolio]

Is Targovax going to be the next big game changer in the Immuno-Oncology field?

Targovax and Oncos Therapetics have recently joined forces to provide a combination treatment in the Immuno-Oncology field. Targovax brings with it a clinical stage peptide vaccine and Oncos Therapeu...

Targovax (TRVX) - Priming immune response in anticancer combos

Edison Investment Research - Pharmaceutical & healthcare - Targovax: Targovax is an immuno-oncology (IO) company specialising in two distinct, but complementary approaches. ONCOS-102 is a genetically ...

Why is Erik Digman Wiklund, CFO of Targovax, reading

Leaders & Readers: I had a chat with Erik Digman Wiklund about why he reads He is the CFO of Targovax ASA, a clinical-stage company focusing on the development of imunno-oncology th...

Targovax's Viral IO Therapy, Anticancer Vaccine Aimed At Combos

Targovax’s strategy is to use its products as immune response primers and combine them with other anticancer therapies, but the...    

Targovax ASA: Exercise price of options

With reference to the Stock exchange notification issued 1 February 2018 regarding options to employees: The exercise price of the granted options is NOK 17.17. The exercise price is eq...

Appointments: Hikma, Ipsen, PeptiDream, Targovax, Moderna and Perrigo

The latest biopharma industry appointments include C-suite hires at Hikma, Ipsen, Sinclair PeptiDream, Targovax, Nicox, Moderna, Antabio and Perrigo; as...   

Targovax ASA: Resolutions to increase the share capital in Targovax ASA in relation to exercise of employee options and settlement of restricted stock units

The board of directors of Targovax ASA (the "Company") has on 27 October 2017, in accordance with the authorisations granted by the general meeting on 5 April 2017, resolved: - to i...

Norwegian Biotech Lands a Blow in the Fight Against Pancreatic Cancer

A Phase I/II trial investigating Targovax’s pancreatic cancer candidate, TG01, saw it keep 100% of trial participants alive 1 year post-surgery. Targovax develops immuno-oncology therapies targe...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [1 Associated Companies listed on BioPortfolio]


Targovax was started in October 2010 to develop TG01, a vaccine targeting pancreatic cancer. TG01 is based on research from The Radium Hospital and Norsk Hydro in the end of the 9...

More Information about "Targovax" on BioPortfolio

We have published hundreds of Targovax news stories on BioPortfolio along with dozens of Targovax Clinical Trials and PubMed Articles about Targovax for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Targovax Companies in our database. You can also find out about relevant Targovax Drugs and Medications on this site too.

Quick Search


Relevant Topics

Pancreatitis Acute pancreatitis is inflammation of the pancreas caused by the release of activated pancreatic enzymes. Common triggers are biliary tract disease and chronic heavy alcohol intake.  Diagnosis is based on clinical presentation...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Corporate Database Quicklinks

Searches Linking to this Company Record